Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PCNA | P12004 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396368 | 0.93 | SLC7A5 (0.42) | SLC7A5MMP2PTGS2 | |
| SCHEMBL13396387 | 0.85 | PTGS2 (0.37) | PTGS2 | |
| SCHEMBL13396493 | 0.83 | KCNH2 (0.36) | PTGS2 | |
| SCHEMBL8933432 | 0.83 | MMP2 (0.54) | SLC7A5MMP2ALDH1A1 | |
| SCHEMBL6559349 | 0.83 | MMP2 (0.54) | SLC7A5MMP2ALDH1A1 | |
| SCHEMBL9052704 | 0.83 | MMP2 (0.54) | SLC7A5MMP2ALDH1A1 | |
| SCHEMBL13396373 | 0.81 | SLC7A5 (0.47) | SLC7A5MMP2PTGS2ALDH1A1HDAC8 | |
| SCHEMBL13396468 | 0.81 | FFAR1 (0.39) | PTGS2 | |
| SCHEMBL13416250 | 0.81 | SLC7A5 (0.46) | SLC7A5NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1832905 | 0.80 | SLC7A5 (0.48) | SLC7A5MMP2PTGS2ALDH1A1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | SLC7A5 4040/4885NPC1 2194/4885MAPT 2611/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | SLC7A5 4181/4885NPC1 2153/4885MAPT 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.